The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Anti–microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways
Open accessAbstract
MicroRNA-21 (miR-21) contributes to the pathogenesis of fibrogenic diseases in multiple organs, including the kidneys, potentially by silencing metabolic pathways that are critical for cellular ATP generation, ROS production, and inflammatory signaling. Here, we developed highly specific oligonucleotides that distribute to the kidney and inhibit miR-21 function when administered subcutaneously and evaluated the therapeutic potential of these anti-miR-21 oligonucleotides in chronic kidney disease. In a murine model of Alport nephropathy, miR-21 silencing did not produce any adverse effects and resulted in substantially milder kidney disease, with minimal albuminuria and dysfunction, compared with vehicle-treated mice. miR-21 silencing dramatically improved survival of Alport mice and reduced histological end points, including glomerulosclerosis, interstitial fibrosis, tubular injury, and inflammation. Anti-miR-21 enhanced PPARα/retinoid X receptor (PPARα/RXR) activity and downstream signaling pathways in glomerular, tubular, and interstitial cells. Moreover, miR-21 silencing enhanced mitochondrial function, which reduced mitochondrial ROS production and thus preserved tubular functions. Inhibition of miR-21 was protective against TGF-β-induced fibrogenesis and inflammation in glomerular and interstitial cells, likely as the result of enhanced PPARα/RXR activity and improved mitochondrial function. Together, these results demonstrate that inhibition of miR-21 represents a potential therapeutic strategy for chronic kidney diseases including Alport nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Fate Tracing Reveals the Pericyte and Not Epithelial Origin of Myofibroblasts in Kidney Fibrosis
Humphreys, B. D., Lin, S.-L., Kobayashi, A., Hudson, T. E., Nowlin, B. T., Bonventre, J. V., Valerius, M. T., McMahon, A. P., & Duffield, J. S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090517 · Cited by 1,442
Self-citationAlport's Syndrome, Goodpasture's Syndrome, and Type IV Collagen
Hudson, B. G., Tryggvason, K., Sundaramoorthy, M., & Neilson, E. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022296 · Cited by 963
Molecular mechanisms of diabetic kidney disease
Reidy, K., Kang, H. M., Hostetter, T., & Susztak, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72271 · Cited by 909
Therapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Self-citationMultiple loci associated with indices of renal function and chronic kidney disease
Köttgen, A., Glazer, N. L., Dehghan, A., Hwang, S.-J., Katz, R., Li, M., Yang, Q., Gudnason, V., Launer, L. J., Harris, T. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.377 · Cited by 647
Cellular and molecular mechanisms in kidney fibrosis
Duffield, J. S. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72267 · Cited by 629
Self-citationMicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways
Chau, B. N., Xin, C., Hartner, J., Ren, S., Castano, A. P., Linn, G., Li, J., Tran, P. T., Kaimal, V., Huang, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003205 · Cited by 587
Self-citationmTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538
Uncoupling proteins and the control of mitochondrial reactive oxygen species production
Mailloux, R. J., & Harper, M.-E. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.022 · Cited by 537
Oxidative Stress in Diabetic Nephropathy
Kashihara, N., Haruna, Y., K. Kondeti, V., & S. Kanwar, Y. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710793348581 · Cited by 464
AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function
Dugan, L. L., You, Y.-H., Ali, S. S., Diamond-Stanic, M., Miyamoto, S., DeCleves, A.-E., Andreyev, A., Quach, T., Ly, S., Shekhtman, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66218 · Cited by 456
Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome.
Cosgrove, D., Meehan, D. T., Grunkemeyer, J. A., Kornak, J. M., Sayers, R., Hunter, W. J., & Samuelson, G. C. (1996) · Genes & Development · doi:10.1101/gad.10.23.2981 · Cited by 395
Identification of a microRNA signature of renal ischemia reperfusion injury
Godwin, J. G., Ge, X., Stephan, K., Jurisch, A., Tullius, S. G., & Iacomini, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912701107 · Cited by 373
miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes
Zhong, X., Chung, A. C. K., Chen, H. Y., Dong, Y., Meng, X. M., Li, R., Yang, W., Hou, F. F., & Lan, H. Y. (2013) · Diabetologia · doi:10.1007/s00125-012-2804-x · Cited by 355
Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice
Asada, N., Takase, M., Nakamura, J., Oguchi, A., Asada, M., Suzuki, N., Yamamura, K.-I., Nagoshi, N., Shibata, S., Rao, T. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57301 · Cited by 347
Nitric oxide, oxidative stress, and progression of chronic renal failure
Modlinger, P. S., Wilcox, C. S., & Aslam, S. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2004.04.007 · Cited by 283
Alport syndrome—insights from basic and clinical research
Kruegel, J., Rubel, D., & Gross, O. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.259 · Cited by 276
Antisense Drug Technology: Principles: Strategies, and Applications
(2021) · CRC Press eBooks · doi:10.1201/9781420002546 · Cited by 268
A short history of a short RNA
Lee, R., Feinbaum, R., & Ambros, V. (2004) · Cell · doi:10.1016/s0092-8674(04)00035-2 · Cited by 224
Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport
Yeung, C. K., Shen, D. D., Thummel, K. E., & Himmelfarb, J. (2014) · Kidney International · doi:10.1038/ki.2013.399 · Cited by 219
Self-citationGross, O., Beirowski, B., Koepke, M.-L., Kuck, J., Reiner, M., Addicks, K., Smyth, N., Schulze-Lohoff, E., & Weber, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00779.x · Cited by 218
Potent inhibition of microRNA in vivo without degradation
Davis, S., Propp, S., Freier, S. M., Jones, L. E., Serra, M. J., Kinberger, G., Bhat, B., Swayze, E. E., Bennett, C. F., & Esau, C. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn904 · Cited by 200
Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition
(2007) · CRC Press eBooks · doi:10.1201/9780849387951 · Cited by 181
Mechanisms of fibrosis: the role of the pericyte
Schrimpf, C., & Duffield, J. S. (2011) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e328344c3d4 · Cited by 172
Self-citationMolecular basis of organ fibrosis: Potential therapeutic approaches
Ghosh, A. K., Quaggin, S. E., & Vaughan, D. E. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213489441 · Cited by 155
Snyder, J. J., Foley, R. N., & Collins, A. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.034 · Cited by 116
miR-21 and miR-214 Are Consistently Modulated during Renal Injury in Rodent Models
Denby, L., Ramdas, V., McBride, M., Wang, J., Robinson, H., McClure, J., Crawford, W., Lu, R., Hillyard, D. Z., Khanin, R., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.021 · Cited by 116
Alvarez, M. L., & DiStefano, J. K. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.010 · Cited by 114
Ninichuk, V., Groß, O., Reichel, C. A., Khandoga, A., Pawar, R. D., Ciubar, R., Segerer, S., Belemezova, E., Radomska, E., Luckow, B., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004100871 · Cited by 100
Krick, S., Shi, S., Ju, W., Faul, C., Tsai, S., Mundel, P. H., & Böttinger, E. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801146105 · Cited by 95
Li, S., Mariappan, N., Megyesi, J. K., Shank, B. B., Kannan, K., Theus, S. A., Price, P. M., Duffield, J. S., & Portilla, D. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00309.2013 · Cited by 86
Self-citationIndoxyl Sulfate Induces Nephrovascular Senescence
Niwa, T., & Shimizu, H. (2011) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2011.10.032 · Cited by 81
Molecular genetics of familial hematuric diseases
Deltas, C. C., Pierides, A., & Voskarides, K. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft253 · Cited by 81
Cimini, A., & Cerù, M. P. (2008) · Stem Cell Reviews and Reports · doi:10.1007/s12015-008-9024-2 · Cited by 78
Kang, J. S., Wang, X.-P., Miner, J. H., Morello, R., Sado, Y., Abrahamson, D. R., & Borza, D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006020165 · Cited by 66
Self-citationGLUT1 Regulation of the Pro-Sclerotic Mediators of Diabetic Nephropathy
Heilig, C. W., Deb, D. K., Abdul, A., Riaz, H., James, L. R., Salameh, J., & Nahman, N. S. (2013) · American Journal of Nephrology · doi:10.1159/000351989 · Cited by 61
Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs
Yu, R., Geary, R., & Levin, A. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-14 · Cited by 59
JAK-STAT and the renin-angiotensin system
Satou, R., & González-Villalobos, R. A. (2012) · JAK-STAT · doi:10.4161/jkst.22729 · Cited by 57
Tumour necrosis factor‐α drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis
Ryu, M., Mulay, S. R., Miosge, N., Groß, O., & Anders, H. (2011) · The Journal of Pathology · doi:10.1002/path.2979 · Cited by 56
Alport syndrome with diffuse leiomyomatosis
Anker, M., Arnemann, J., Neumann, K., Ahrens, P., Schmidt, H., & König, R. (2003) · American Journal of Medical Genetics. Part A · doi:10.1002/ajmg.a.20019 · Cited by 51
MicroRNA Circuits in Transforming Growth Factor-β Actions and Diabetic Nephropathy
Kato, M. V., & Natarajan, R. D. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.04.004 · Cited by 50
The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats
Boor, P., Celec, P., Martin, I. V., Villa, L., Hodosy, J., Klenovicsová, K., Esposito, C., Schäfer, S., Albrecht-Küpper, B. E., Ostendorf, T., et al. (2011) · Kidney International · doi:10.1038/ki.2011.254 · Cited by 48
The Medicinal Chemistry of Oligonucleotides
Swayze, E. E., & Bhat, B. (2007) · CRC Press eBooks · doi:10.1201/9780849387951.ch6 · Cited by 39
Zhou, T., Drummen, G. P. C., Jiang, Z., Long, Y.-B., & Qin, Y. (2013) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2013.838786 · Cited by 28
The Medicinal Chemistry of Oligonucleotides
Swayze, E. E., & Bhat, B. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-13 · Cited by 26
MicroRNAs as potential therapeutic targets in kidney disease
Gomez, I. G., Grafals, M., Portilla, D., & Duffield, J. S. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.12.011 · Cited by 22
Self-citation
Cited by
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Renal tubule injury: a driving force toward chronic kidney disease
Liu, B.-C., Tang, T.-T., Lv, L.-L., & Lan, H.-Y. (2018) · Kidney International · doi:10.1016/j.kint.2017.09.033 · Cited by 913
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P., & Lee, S.-S. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.005 · Cited by 731
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Metadata
- Authors
- Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., Xia, T.-H., Liu, X., Borza, D.-B., Grafals, M., Shankland, S. J., Himmelfarb, J., Portilla, D., Liu, S., Chau, B. N., & Duffield, J. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-11-21
- Volume
- 125
- Issue
- 1
- Pages
- 141-156
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2102750482
- Cited by
- 413
- References
- 48
- FWCI
- 21.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.